GENEVA—Toxicities from targeted agents used in lung cancer differ from those encountered with other drugs but can be managed successfully if recognized early and treated. At the European Lung Cancer Conference, Silvia Novello MD, PhD, an Assistant Professor of Respiratory Medicine at the Department of Clinical and Biological Sciences of the University of Turin, Italy, told Oncology Times reporter Peter Goodwin how side effects—including diarrhea, metabolic disturbances and electrolyte imbalances—to treatments targeting EGFR and immune checkpoints have been managed in her clinic, demonstrating that careful planning and vigilance can help deliver new-generation drug regimens on-dose on-time to achieve significant improvements in outcomes.
You may also like...
International Research and Consensus Needed to Interpret Breast Cancer Genomics Data 27 Mar, 2015 Malaria and STIs/RTIs Among Pregnant Women in sub-Saharan Africa 7 Oct, 2012 Combining Checkpoint Inhibition With Other Therapies for Lung Cancer 22 Apr, 2015 Malaria—Insecticide Research Promises To Beat Mosquito Resistance 2 Jan, 2012
- Previous story No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed
- Next story Three Drug Regimen Best for Squamous Non Small Cell Lung Cancer—Even in Older Patients
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014